Dopaminergic Therapy for Frontotemporal Dementia Patients

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-04-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: petimagingalzheimerthe patientbrain
  Phrases that lowered it: evaluate themultipleto evaluatescreeningand safety
• Minimum age: 40 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Number of arms: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 15.7% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 68.2% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 10 (raises risk) · Sponsor's track record
• Sponsor's past trials: 10 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease NCT03250741 · started 2016 · scored riskier than 54% of active trials completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) NCT01626378 · started 2013 · scored riskier than 80% of active trials completed
• Effects of Tolcapone on Frontotemporal Dementia NCT00604591 · started 2008 · scored riskier than 22% of active trials completed
• Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease NCT02103465 · started 2013 · scored riskier than 18% of active trials terminated
• A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease NCT01723904 · started 2012 · scored riskier than 14% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.